ClinicalTrials.gg

Program

TCC1727

A development code. Also written as “TCC1727 tablet 90mg”, “TCC1727 tablet 120mg” and “TCC1727 tablet 160mg”.

In Sino Biopharmaceutical's pipeline, ATR选择性抑制剂. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Sino Biopharmaceutical.

Furthest: phase 2, since Jul 14, 20232 company-led studies, 2 open or runningNext primary completion: Sep 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical22 open or runningphase 2since Jul 14, 2023Jul 14, 2023Sep 30, 2028phase 2 · NCT07371663
  • Named in Sino Biopharmaceutical’s own pipeline as TCC1727, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2023First study: phase 2 study in Patients with Advanced Solid TumorsFirst studyNCT05970016 · 56 planned · China
  2. Dec 15, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07371663 · 266 planned · China

Ahead

  1. Sep 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07371663

TargetBeta

“ATR选择性抑制剂”the company's pipeline, read by Claude · source

Other programs on ATR

ProgramCompanyFurthest phaseStudies
ceralasertibruleAstraZenecaphase 316
FXS887ruleFosun Pharmaphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07371663Carcinoma, Non-Small-Cell Lung · China2RecruitingSep 30, 2028266
NCT05970016Patients with Advanced Solid Tumors · China2RecruitingJul 30, 202556

How it is read

Names in the registry

  • “TCC1727 tablet 90mg”, 1 entry
  • “TCC1727 tablet 120mg”, 1 entry
  • “TCC1727 tablet 160mg”, 1 entry
  • “TCC1727 tablet(1)”, 1 entry
  • “TCC1727 tablet(2)”, 1 entry

Codes read as this program: TCC1727.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.